Posts

Cancer detection test maker Grail, acquired by Illumina Inc. last year despite ongoing antitrust challenges, on Tuesday said it would expand use of its flagship Galleri cancer diagnostic test through a new agreement with life insurer John Hancock, a division of Manulife Financial.

U.S. life sciences firm Illumina will have to divest biotechnology company Grail after an EU veto of the $7.1 billion acquisition over concerns it would hurt competition and stifle innovation.

In the decision, a judge ruled for Illumina and rejected the FTC’s position that the deal would adversely affect competition in a putative market for multi-cancer early detection (MCED) tests.